Comparison of efficacy of methotrexate and azathioprine in chronic resistant atopic eczema
DOI:
https://doi.org/10.66344/jpad.v33i3.2459Keywords:
eczema, atopic dermatitis, chronic ecezmaAbstract
Background Atopic dermatitis is a common dermatological problem in children and adults. It is associated with poor quality of life, significant financial burdens, and poor mental health. There are many topical and systemic treatment modalities for chronic atopic eczema. Systemic treatment like Methotrexate and azathioprine is indicated in chronic atopic eczema patients resistant to topical steroids.
Objective To assess the efficiency of methotrexate versus azathioprine in chronic resistant eczema.
Methods This study was conducted in the Department of Dermatology in Nishtar Hospital, Multan from January 2012 to July 2012. 270 patients with clinically resistant atopic eczema were included and detailed history and examinations were done. 135 patients were given weekly oral methotrexate and 135 were given oral azathioprine weekly. Patients were followed up for 12 weeks. All data were recorded in a predesigned proforma.
Results MTX treated group showed statistically significant better efficacy of (51%) when compared to AZA (36%) at 12 weeks.
Conclusion Methotrexate is more efficacious compared to azathioprine for the treatment of patients with chronic resistant atopic eczema.
References
1. Lee JH, Yun SJ, Lee JB, Lee SC. Therapeutic Efficacy and Safety of Methotrexate in Moderate-to-Severe Atopic Dermatitis: A Retrospective Study of Korean Patients at Tertiary Referral Hospital. Ann Dermatol. 2020;32(5):402-8.
2. Johansson SG, Bieber T, Dahl R, et al.: Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6.
3. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3-16.
4. Mortimer K, Lesosky M, García-Marcos L, et al.: Global Asthma Network Phase I Study Group. The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study. Eur Respir J. 2022 Sep 15;60(3):2102865.
5. Blome C, Radtke MA, Eissing L, Augustin M. Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit. Am J Clin Dermatol. 2016 Apr;17(2):163-9.
6. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26(3):633-40.
7. Wollenberg A, Kinberger M, Arents B, et al.: European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409-31.
8. Gerbens LAA, Hamann SAS, Brouwer MWD, Roekevisch E, Leeflang MMG, Spuls PI. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol. 2018;178(6):1288-96.
9. Shen S, O'Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol. 2012;53(1):1-18.
10. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353-9.
11. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007 Feb;156(2):346-51.
12. Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J. 2008;10(6):413-4. https://pubmed.ncbi.nlm.nih.gov/18669134/.
13. Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol. 2008;33(6):710-1.
14. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367(9513):839-46.
15. Bracho-Borro M, Franco-Ruiz PA, Magaña M. The use of azathioprine in atopic dermatitis: A review. Dermatol Ther. 2022;35(9):e15665.
16. Drucker AM, Ellis AG, Bohdanowicz M, et al.: Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. JAMA Dermatol. 2020 1;156(6):659-667.
17. Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836-45.
18. Liu W, Cai J, Sun C, Zou Z, Zhang J, Huang C. Time-trends for eczema prevalences among children and adults from 1985 to 2015 in China: a systematic review. BMC Public Health. 2022;22(1):1294.
19. Goujon C, Viguier M, Staumont-Sallé D, et al.: Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. J Allergy Clin Immunol Pract. 2018;6(2):562-569.
20. Shaffrali FC, Colver GB, Messenger AG, Gawkrodger DJ. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol. 2003;48(3):417-9.
21. Shah N, Alhusayen R, Walsh S, Shear NH. Methotrexate in the Treatment of Moderate to Severe Atopic Dermatitis: A Retrospective Study. J Cutan Med Surg. 2018;22(5):484-487.
22. Syed AR, Aman S, Nadeem M, Kazmi AH. The efficacy and safety of oral methotrexate in chronic eczema. J Pak Assoc Dermatol. https://www.jpad.com.pk/index.php/jpad/article/view/549
23. Berth-Jones J, Takwale A, Tan E, et al.: Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147(2):324-30.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Humaira Shamim, Mahwash Rana, Sumaira Hanif, Nadia Sultan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
